Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4632612 | 0.64 | ADORA2A (0.41) | CASRKMT2AMAPK1LMNAKDM4E | |
| SCHEMBL746264 | 0.64 | LMNA (0.41) | CASRKMT2ALMNAKDM4EBRAF | |
| SCHEMBL15153407 | 0.64 | HDAC6 (0.36) | KMT2A | |
| SCHEMBL746263 | 0.63 | LMNA (0.39) | CASRKMT2AMAPK1LMNAKDM4E | |
| SCHEMBL12614889 | 0.59 | KDM4E (0.45) | CASRKMT2AMAPK1KDM4E | |
| SCHEMBL739913 | 0.58 | AURKA (0.42) | CASRKMT2ALMNAKDM4E | |
| SCHEMBL11035301 | 0.57 | KDM4E (0.47) | KMT2ALMNAKDM4E | |
| SCHEMBL5980836 | 0.57 | KMT2A (0.45) | KMT2AMAPK1LMNAKDM4EADORA3 | |
| SCHEMBL1981191 | 0.56 | DGAT2 (0.53) | KMT2AMAPK1LMNAKDM4EEPHX2 | |
| SCHEMBL3835902 | 0.56 | PPARG (0.52) | KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138217-B2 | Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-03-20 | — | — | US | disclosed |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | MAP3K19, MAP3K1, MAP3K3 | CASR 4085/4885KMT2A 1586/4885MAPK1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.